WHAT WE DO
Benevolent News Hub
In the media
AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio
Top 10 Companies Combining AI and Drug Discovery in Europe
Biotechs harness AI in battle against Covid-19
How A.I. Steered Doctors Toward a Possible Coronavirus Treatment.
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020
What to expect from your internship at BenevolentAI
What makes the best tech internships? Learn about what our 2020 interns have been up to, and how interning at Benevolent helped their career development.
Dec 2, 2020
Meet the BenevolentAI 2020 Intern Cohort
What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.
Nov 26, 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.
Nov 20, 2020
BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery
BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.
Nov 17, 2020
Careers with Impact: 5 learnings from machine learning applied drug discovery
Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:
Nov 17, 2020
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Nov 13, 2020
Sir Nigel Shadbolt joins BenevolentAI as a non-executive director
BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.
Nov 3, 2020
Receive our latest news
Check our Engineering Blog
How to use Makefiles to run a simple Map Reduce Data Pipeline
events & Conferences
RSA Inspiring Leaders Webinar w/ Jackie Hunter
Wired Health w/ Joanna Shields
Cambridge Science Festival / Anne Phelan
AI in Drug Discovery Conference w/ Nathan Brown
Data Diversity initiative
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy